Please login to the form below

Not currently logged in
Email:
Password:

Seroxat

This page shows the latest Seroxat news and features for those working in and with pharma, biotech and healthcare.

UK government fines GSK over 'pay-for-delay' deals

UK government fines GSK over 'pay-for-delay' deals

The UK's Competition &Markets Authority has fined GlaxoSmithKline (GSK) and several other companies for delaying the availability of generic versions of its antidepressant Seroxat. ... The CMA's decision relates to activities between 2001 and 2004 in

Latest news

  • GSK holds on to older products GSK holds on to older products

    £185m. Other products in GSK's established portfolio with declining sales include antidepressant Seroxat/Paxil (paroxetine) and antiviral drug Valtrex (valacyclovir), both of which had a double digit fall in revenues

  • GSK plans to sell off older products GSK plans to sell off older products

    Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established

  • Hisamitsu's Noven unit signs Brisdelle deal with Shionogi Hisamitsu's Noven unit signs Brisdelle deal with Shionogi

    Brisdelle contains 7.5mg of paroxetine, which - at a slightly higher dose - is the active ingredient in antidepressants like GlaxoSmithKline's now off-patent Seroxat/Paxil. ... In common with Seroxat Brisdelle also carries a Boxed Warning about

  • This month in 2000: The formation of GSK This month in 2000: The formation of GSK

    Since then, GSK has been consistently one of the world's best-performing healthcare companies, led by such prescription drugs as asthma treatment Advair/Seretide (fluticasone/salmeterol) and the antidepressant

  • Pay-for-delay deals lead to inflated drug prices says study Pay-for-delay deals lead to inflated drug prices says study

    Of these companies, Lundbeck is facing a penalty of 240m. Meanwhile, the UK Office of Fair Trading has accused GlaxoSmithKline of blocking the entry of generic versions of its Seroxat (paroxetine)

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics